Abstract: The present study aims to discuss the efficacy of sodium glycididazole ( CMNa ), combined with concurrent radiochemotherapy, for advanced cervical carcinoma and to observe its adverse reactions. Methods: A total of 60 patients with cervical carcinoma were randomly classified into two groups. There were 30 cases in the sensitization group ( group A: CMNa combined with concomitant radiochemotherapy ) and the other 30 cases in the control group ( group B: concomitant radiochemotherapy ). The method of radiochemotherapy was the same in both groups. Aside from radiochemotherapy, the patients in Group A were concurrently administered with an intravenous drip of CMNa 800 mg/m2 at 1 h prior to irradiation therapy, three times a week for 6 to 7 wk. The patients in group B were given concomitant radiochemotherapy only. Results: After the treatment, 25 ( 83.3% ) of the 30 patients in group A achieved complete remission ( CR ), and 18 ( 60% ) of the 30 patients in group B achieved CR, with significant differences in the CR rates between the two groups ( P < 0.05 ). Both groups achieved an overall response rate (partial remission+CR) of 100% at the end of the treatment. At three months after radiotherapy, the CR rate was 86.7% ( 26/30 ) in group A, with a total effective rate of 93.3% ( 28/30 ). The CR rate was 80% ( 24/30 ) in group B, and the total effective rate was 96.7% ( 29/30 ). There were no significant differences between the two groups in the CR and the overall response rate after three months of therapy ( P > 0.05 ). There were no significant differences in the degree of adverse reactions between the two groups. Conclusion: Sodium glycididazole can improve the complete remission rate in patients with local advanced cervical carcinoma treated with concurrent radiochemotherapy, without more severe toxicity. However, to understand long-term effects of sodium glycididazole, a large sample size and further observation are needed.